Newer therapies - DiabetesontheNet

Highlights from the 58th Annual Meeting of the European Association for the Study of Diabetes

Pam Brown summarises the key presentations from a primary care perspective.

3 Oct 2022

Journal club: My patient is on a statin. Why are they not also on an SGLT2 inhibitor?

Discussion of recent notable papers. Calculating the costs of diabetes complications, and how to reduce their risk.

5 Sep 2022

Ideas for improving patient outcomes: the quirky and the ones in the guidelines

Reviewing the latest evidence, Vinod Patel offers a number of changes that could be made to improve outcomes of people with type 2 diabetes.

18 Aug 2022

Do SGLT2 inhibitors protect against pneumonia and sepsis?

Reductions in pneumonia and sepsis, as well as death due to infection, seen with SGLT2 inhibitors versus DPP-4 inhibitors.

18 Aug 2022

Renal outcomes with SGLT2 versus DPP-4 inhibitors: CPRD data

SGLT2is are associated with a reduced risk of kidney disease progression and death compared with DPP-4is.

18 Aug 2022

Editorial: Implications of prescribing SGLT2 inhibitors to a wider population

SGLT2i licensing extensions and their implications for primary care.

12 Jul 2022

Latest news: Draft ADA/EASD advice, more data on tirzepatide, dulaglutide in paediatric T2D, and tech-assisted remission

Headlines from the American Diabetes Association 82nd Scientific Sessions, held in New Orleans and online from 3rd to 7th June.

30 Jun 2022

The evolving role of SGLT2 inhibitors

A review of SGLT2 inhibitors and their benefits beyond glucose lowering, their place in the latest guidelines, and how to use them safely and effectively.

30 Jun 2022

News in brief: Highlights of the American Diabetes Association 82nd Scientific Sessions

Key stories for primary care from the conference.

15 Jun 2022

My patient is on a statin. Why are they not also on an SGLT2 inhibitor?

Vinod Patel highlights the costs associated with diabetes complications and the savings that can be made by preventing them.

10 Jun 2022

Simulated cost-effectiveness of SGLT2 inhibitors versus DPP-4 inhibitors

Cardiovascular benefits make SGLT2 inhibitors highly cost-effective in people with type 2 diabetes regardless of CVD history.

10 Jun 2022

Cardiorenal effects of dapagliflozin according to renal function at initiation

Cardiorenal benefits of dapagliflozin are consistent across KDIGO risk categories, both in people with and without type 2 diabetes.

10 Jun 2022

Diabetes Distilled: The twincretin tirzepatide – a promising treatment for NAFLD

The dual GIP/GLP-1 receptor agonist halves liver fat content in people with type 2 diabetes and NAFLD.

13 May 2022

NICE type 2 diabetes management guidance: What’s new?

Su Down reviews the 2022 changes to the NICE NG28 guideline Type 2 diabetes in adults: management.

22 Apr 2022

Interactive case study: Managing type 2 diabetes during Ramadan

Two scenarios to relating to the safe management of type 2 diabetes during Ramadan.

16 Mar 2022

Diabetes Distilled: Updated NICE guidance on type 2 diabetes: Key points for primary care

What the NG28 update means for prescribing in primary care.

10 Mar 2022

Latest news: JBDS-IP guidelines, sepsis, finerenone, paediatric type 2 diabetes and a new pre-filled glucagon pen

Stay abreast of the latest news that could impact diabetes nursing.

1 Mar 2022

Efficacy and safety of SGLT2 inhibitors in a real-world type 1 diabetes cohort

Retrospective study shows SGLT2 inhibitors are effective as an adjunct to insulin, although DKA remains a concern.

15 Feb 2022